Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research

Only a handful of US research labs have the ability to make cancer immunotherapies, called CAR T-cell therapies, for use in human studies. That has largely limited CAR T-cell research to studies of small groups of patients at individual hospitals. To accelerate and speed up that research, NCI has established a program at its labs in Frederick, Maryland, to manufacture CAR T-cell therapies for use in clinical trials at multiple hospitals.

Learn more about the manufacturing initiative in this NCI Cancer Currents blog post: https://www.cancer.gov/news-events/ca...

Learn more about CAR T-cell therapy and other immunotherapies: https://www.cancer.gov/about-cancer/t...

Fully-accessible 508-compliant version of this video: https://smartplayer.captionsync.com/p...

Video of the CliniMACS Prodigy® system courtesy of Miltenyi Biotec.